NEW YORK, September 1, 2016 /PRNewswire/ --
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to report on its asset acquisition and an update on corporate development.
While the summer months have been typically slow, we have made good progress on all fronts. We are currently finalizing the closing conditions required to formalize the exclusive licensing of an FDA approved drug from a U.S. Company focused on the development and production of generic radiopharmaceuticals. The expected addition of this asset to our pipeline will be extremely timely, as all stakeholders in the healthcare space look to make more affordable drugs available to patients.
Regarding our current asset, MAN-01 for the treatment of glaucoma, our partner, Mannin Research is progressing well in its pre-clinical lead candidate optimization of a small molecule for a topical route of administration.
Mannin is continuing strategic partnership discussions with companies and technologies that will strengthen Mannin's intellectual property portfolio in the Tie2/TEK mechanism of action market. Mannin is also establishing research and development partnerships with non-governmental organizations to provide direct support for the MAN-01 program.
Q BioMed has been conducting due diligence on several other potential assets to expand the ophthalmology pipeline within Q BioMed. These include implantable devices and biomarker diagnostics. In addition, we have been working with additional potential advisory experts to add to our team. We will make details of these available as they materialize.
Our CEO Denis Corin was recently interviewed on The Stock Radio. The interview can be accessed here.
Please visit our website http://www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.
About Q BioMed Inc.
Q BioMed Inc."Q" is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Q BioMed Inc.
SOURCE Q BioMed Inc